Ascendis Pharma A/S (ASND)
$229.23+2.94%Close
SELLRECOVERY · day 8
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $14.2B
- Beta
- 0.37
- P/E (TTM)
- 16.60
- Short % float
- 5.66%
- Days to cover
- 3.7
- SI change
- -12.1%
- 1W
- +0.60%
- 1M
- -12.25%
- vs SPY 1W
- -0.56%
- vs SPY 1M
- -15.24%
Industry peers
FMP comparable companies · ranked by market cap
- UTHRBUYUnited Therapeutics Corporation$23.3BRECOVERYQ 20$549.16+3.07%
- INSMSELLInsmed Incorporated$21.8BCRISISQ 13$100.60+0.12%
- NBIXSELLNeurocrine Biosciences, Inc.$14.3BRECOVERYQ 17$142.44+0.84%
- CORTBUYCorcept Therapeutics Incorporated$13.1BRECOVERYQ 22$121.19+2.24%
- BMRNSELLBioMarin Pharmaceutical Inc.$10.6BBEARQ 12$54.80-0.16%
- MBXSELLMBX Biosciences, Inc. Common Stock$2.5BCRISISQ 38$53.24-0.02%
- XERSBUYXeris Biopharma Holdings, Inc.$1.8BBULLQ -1$10.48+2.85%
- SEPNSELLSepterna Inc$1.7BRECOVERYQ 28$38.37+3.98%
- STOKSELLStoke Therapeutics, Inc.$1.6BCRISISQ 11$24.74+3.30%
- RAREBUYUltragenyx Pharmaceutical Inc.$1.5BRECOVERYQ -6$15.48+1.24%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 26
- VALUE
- 16
- GROWTH
- 44
- GARP
- 15
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC114.3%
REV YoY-
ROE190.4%
EPS YoY-
ROA33.1%
GROSS90
OP10
NET72
[VALUATION]
P/E TTM16.60
P/E FWD28.31
SECTOR PE20.47
INDUSTRY PE13.95
P/B9.00
P/FCF-
EV/EBITDA155.08
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E31.33
ALTMAN Z-
CURR RATIO2.99
ND/EBITDA-
BETA0.37
Company news
FAQ
- What is LOPJLB’s current signal on ASND?
- LOPJLB’s latest quantitative signal on Ascendis Pharma A/S (ASND) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is ASND in?
- Ascendis Pharma A/S (ASND) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Ascendis Pharma A/S (ASND) do?
- Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. T…